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Abstract
Pretubulysin is a natural product that is found in strains of myxobacteria in only minute amounts. It represents the first
enzyme-free intermediate in the biosynthesis of tubulysins and undergoes post-assembly acylation and oxidation reactions.
Pretubulysin inhibits the growth of cultured mammalian cells, as do tubulysins, which are already in advanced preclinical
development as anticancer and antiangiogenic agents. The mechanism of action of this highly potent compound class
involves the depolymerization of microtubules, thereby inducing mitotic arrest. Supply issues with naturally occurring
derivatives can now be circumvented by the total synthesis of pretubulysin, which, in contrast to tubulysin, is synthetically
accessible in gram-scale quantities. We show that the simplified precursor is nearly equally potent to the parent compound.
Pretubulysin induces apoptosis and inhibits cancer cell migration and tubulin assembly in vitro. Consequently, pretubulysin
appears to be an ideal candidate for future development in preclinical trials and is a very promising early lead structure in
cancer therapy.
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Introduction
Natural products play a very significant role in drug discovery
and the development of novel pharmaceuticals, particularly
anticancer compounds and antiinfective agents. The apparent
drawbacks of these compounds, such as production, continuous
supply, and the complex synthetic routes involved in natural
product chemistry, are outweighed by the advantages of chemical
diversity and numerous biological activities (‘privileged struc-
tures’).[1,2]
Traditionally, the main sources of natural products have been
soil bacteria, fungi, and higher plants, but in recent decades,
cyanobacteria and marine organisms have also been of particular
interest.[3] Among microbial sources, actinomycetes remain the
best-studied organisms and represent a very rich source of
bioactive secondary metabolites. Nevertheless, the success rates
for the discovery of novel chemical entities from traditional sources
with potent biological activities has decreased with time.[4,5]
Myxobacteria are increasingly recognized as proficient producers
of bioactive secondary metabolites. This fascinating and widely
expanding order of d-proteobacteria has a unique and complex
developmental life cycle,[6,7] and in the last three decades,
myxobacteria have become an outstanding source of natural
products with unique structures, a broad spectrum of activities,
and often completely novel mechanisms of action.[8,9]
As reviewed by Newman and Cragg in 2012,[10] over 60% of
anticancer drugs in the last 30 years have originated from natural
products. Among the decisive cellular targets, microtubules have
played a major role, especially since the Vinca alkaloids vinblastine
and vincristine entered the market in the early 1960s. Moreover,
chemotherapeutics belonging to this compound class continue to
be highly valuable as part of the pharmacopoeia for cancer
treatment.[11,12] In mammalian cells, microtubules are crucial
for trafficking, signaling, migration, and proliferation. These
dynamic structures are composed of a,b-tubulin heterodimers
that are constantly assembled and disassembled as the microtu-
bules oscillate between growing and shortening phases (dynamic
instability). Most importantly, the suppression of these dynamics
by small molecules ultimately results in mitotic arrest and, in turn,
the inhibition of cell proliferation and the induction of apoptosis.
The search for novel microtubule-interacting compounds is
primarily motivated by the need to overcome the typical resistance
acquired to these drugs and the neurotoxicity of these com-
pounds.[13]
To date, six distinct compound classes that are produced by
myxobacteria have been found to directly interfere with the
eukaryotic cytoskeleton by either stabilizing or destabilizing
microtubules (epothilone [14], disorazol [15], and tubulysin [16])
or actin filaments (chivosazol [17], chondramide [18], and
rhizopodin [19]). Of these, microtubule-targeting drugs have been
the subject of concerted efforts to elucidate their biosynthesis, total
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synthesis, and semi-synthesis to improve their pharmacological
properties and yields.[20,21] Epothilone B, a microtubule
stabilizer that acts in a manner similar to that of taxanes, is one
of the highlights of myxobacterial natural product research; its
semisynthetic analog, ixabepilone, was approved in 2007 for the
clinical treatment of advanced breast cancer in the US.[22]
Tubulysins were first discovered by the bioactivity-guided
screening of the myxobacterial strains Archangium gephyra Ar 315
and Angiococcus disciformis An d48. These compounds were
described as very effective microtubule-destabilizing agents with
structural similarity to dolastatin-10 and with GI50 values against
mammalian cells in the picomolar to low nanomolar range.[16]
The identification and molecular analysis of the biosynthetic gene
cluster from A. disciformis An d48 revealed that the secondary
metabolites are assembled by a PKS/NRPS (polyketide synthase/
nonribosomal peptide synthetase) hybrid system that produces
linear tetrapeptides consisting of N-methyl pipecolic acid (Mep)
and isoleucine (Ile) followed by the unusual amino acid tubuvaline
(Tuv) and an a-methylated aromatic c-amino acid either derived
from tyrosine (Tut, tubutyrosine) or phenylalanine (Tup, tubu-
phenylalanine). In this study of the biosynthetic machinery, a
precursor of tubulysin was postulated for the first time; this
precursor is released from the last module in the biosynthetic
assembly line. The enzyme-free precursor, referred to as
‘pretubulysin’, would then undergo oxidation and acylation
reactions to form the natural product.[23] In subsequent studies,
pretubulysin was isolated in minute amounts from A. disciformis and
shortly after, the total synthesis of the natural product was
initiated. Thus, the biosynthetic hypothesis was finally proven by
comparing synthetic and naturally occurring pretubulysin via mass
spectrometry and NMR.[24]
Natural tubulysins can be obtained by fermentation in only
limited amounts (several mg per L), and their isolation requires
multiple chromatographic steps; both the fermentation and
chromatography steps are expensive. As reported by other groups,
the introduction of the rather labile N,O-acetal group at the N-
terminus of Tuv is the most challenging synthesis step and limits
production on a reasonable scale.[25,26] Because of the lack of
this structural moiety in pretubulysin, we are now able to
synthetically produce pretubulysin D in multigram quantities
and thus, circumvent the supply issues typical of most natural
products in preclinical development. Although pretubulysin lacks
the N,O-acetal and acetoxy functionalities of Tuv, these moieties
do not appear to be crucial for biological activity, as determined by
growth inhibition of cancer cell lines.[24,27]
To date, no detailed study on pretubulysin’s effects on cancer
cell lines and purified tubulin has been published. We herein
report the results of comparative biological studies on tubulysins,
pretubulysin and one of pretubulysin’s small precursors derived by
chemical synthesis. We characterized the potential anticancer
properties of these molecules in cell-based and in vitro systems,
and our results strongly suggest that pretubulysin, as a more stable
derivative of tubulysin, has characteristics that are very similar to
those of the original natural products that have been associated
with antimitotic effects. Our findings will aid the development of
pretubulysin, or an even more simplified analog, as a novel
antimitotic agent for tumor therapy.
Results and Discussion
Antiproliferative effects on tumor cell lines
Our initial evaluation of the growth inhibition of cultured cells
was based on tetrazolium salt reduction (MTT assay). Pretubulysin
was active in a low to sub-nanomolar range against various tumor
cell lines.[24,27] Thus, based on the GI50 values, pretubulysin is,
on average, only a factor of 10 or 100 less active than naturally
occurring tubulysin A or D, respectively. We became especially
interested in other even more simplified synthetic precursors
(Figure 1 and S1) and their ability to inhibit the proliferation of
cancer cell lines.
As reported earlier, the high potency of tubulysins is often
unaffected by variations in the C-terminus, whereas N-terminal
methylpipecolic acid (Mep) appears to be crucial for high
potency.[28,29] Here, tubulysins D and A exhibited GI50 values
in the picomolar range against mouse L-929 cells, whereas
pretubulysin was approximately 20-fold less active (5.8 nM). The
removal of the C2-methyl group of Tup led to a further 10-fold
reduction in activity (61.0 nM). Activity was nearly abolished in all
other analogs. When N-Mep was replaced with N-methylsarcosine
in the desmethyl derivative, a significant loss in activity was
observed (8.5 mM). Variants in which the propionate group of Tup
was missing (9.6 mM) or in which the C-terminal amino acid was
missing (14.2 mM) were essentially inactive. Single Mep, MepIle,
and MepIleMeVal building blocks did not inhibit L-929 cells at
concentrations up to 25 mM. Interestingly, the MepIleMe’Val’
derivative in which Val is replaced by the C2-prolonged homolog
(c-amino acid) (compound V, Figure 1) exhibited increased activity
relative to MepIleTuv, with a GI50 value of 6.5 mM against L-929
mouse cells (Figure S1).
We next compared the potencies of tubulysin A and
pretubulysin with respect to inducing the accumulation of cells
in the G2/M phase of the cell cycle, which is a hallmark for
Figure 1. Structural comparison of tubulysin A (R =OH),
tubulysin D (R=H), pretubulysin and a synthetic precursor.
The modifications of all synthetic precursors of pretubulysin (I–VIII) are
highlighted [I: Mep replaced by N-methylsarcosine; II: desmethyl Tup
variant; III: missing propionate of Tup; IV: MepIleTuv; V: MepIleMe’Val’
(c-amino acid); VI: MepIleMeVal; VII: MepIle; VIII: Mep].
doi:10.1371/journal.pone.0037416.g001
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tubulin-disrupting/antimitotic agents (Figure 2 and Table S1). As
expected, pretubulysin is able to halt cells in the G2/M phase after
24 h of treatment. Similar to the results from the initial growth
inhibition experiments with HepG2 cells, the antimitotic activity is
comparable to that of the reference compound tubulysin A.
Approximately 22% of the control cells are in G2/M phase. This
population increases to approximately 73% or 82% after
treatment with 50 nM or 200 nM tubulysin A, respectively;
simultaneously, the G1 population decreases from 53% to less than
10% of the total number of measured cells (Figure 2A). Following
a 24 h incubation with 50 nM pretubulysin, the cells are equally
distributed in G1 (42%) and G2/M (44%) phases, and a more
pronounced mitotic arrest with approximately 70% cells in G2/M
phase is first observed at a concentration of 100 nM or greater
(Figure 2B).
As determined by NMR structural analysis of tubulysin A
bound to tubulin, the aromatic ring of Tut and the thiazole ring of
Tuv form a basal platform in the tubulin-bound state that appears
to be essential for full activity.[29] Although precursor V (Figure 1)
lacks both aromatic rings, we could still observe the induction of
G2/M cell cycle arrest in human hepatocellular carcinoma cells.
At a final concentration of 5 mM, nearly 40% of all viable cells
accumulated in G2/M phase. However, at higher drug concen-
trations, the percentage of viable cells in G2/M further increased
to up to 60% in parallel with an emerging sub-G1 population,
which most likely reflects late apoptotic cells in which the DNA has
already been degraded (Figure 2C). This small pretubulysin
precursor molecule is also likely able to destabilize microtubules to
a certain extent and, in turn, leads to mitotic arrest in HepG2 cells.
Nevertheless, the effect seems to be more nonspecific than that of
pretubulysin itself, a difference that is reflected by a higher toxicity
that is likely due to the greater than 100-fold-higher concentrations
required to observe any effect on the cell cycle.
Complementary to these results, we demonstrated that the long-
term survival of human L3.6pl pancreatic cancer cells decreased
after a 4 h exposure to tubulysins. Over a 6 d treatment period,
the relative number of colonies formed by the cells was reduced to
40% of the control after pretreatment with 1 nM tubulysin A and
to approximately 30% of the control after pretreatment with
50 nM pretubulysin (Figure 3).
Apoptosis induction
The aforementioned mechanisms of mitotic arrest are often
found to trigger molecular signaling of the mitochondrial apoptosis
pathway.[30] DNA fragmentation, effector caspase activation, and
other regulatory events are useful parameters for gaining insight
into the apoptotic mechanisms induced by microtubule-targeting
compounds. Tubulysin A leads to DNA laddering in KB-3.1
cells,[31] and in this study, we clearly confirmed the same effect
for pretubulysin at a comparable concentration range after a 24 h
treatment (Figure 4A).
Antimitotic effects such as the formation of a multipolar spindle
apparatus are believed to occur prior to the induction of apoptosis,
which is accompanied by complete nuclear fragmentation and
DNA laddering.[32,33] All of these typical hallmarks occurred
after treatment with pretubulysin. Treatment of human U-2 OS
Figure 2. Comparison of induced G2/M cell cycle arrest in human HepG2 hepatocellular carcinoma cells. The cells were treated for 24 h
with varying concentrations of A) tubulysin A, B) pretubulysin, or C) pretubulysin precursor V as indicated by cell cycle histograms. Fixed cells were
analyzed after propidium iodide (PI) staining by flow cytometric measurements (FCM), and histograms of gated populations (excluding debris) were
obtained by the Dean-Jett-Fox algorithm (quantitative data can be found as supporting material; Table S1). Histograms are representative results of a
set of independent experiments. Arrows indicate the sub-G1 cell populations.
doi:10.1371/journal.pone.0037416.g002
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osteosarcoma cells with 25 nM pretubulysin resulted in partly
fragmented nuclei and abnormal accumulation of microtubules
around the periphery of the nuclei. At higher concentrations,
microtubules were completely depolymerized, and most of the cells
showed fragmentation of the nuclei (Figure 4B). At these
pretubulysin concentrations, normal mitotic cells, which were
present among the control cells, were no longer observed. Instead,
cells with abnormal multipolar spindle pole structures were present
(data not shown).
The proto-oncoprotein Bcl-2 (B cell lymphoma 2) is a key player
in mitochondrial apoptosis because its phosphorylation status is
linked to cell growth, the regulation of apoptosis, and the cellular
redox status.[34] Inactivation, i.e., phosphorylation, of antiapop-
totic Bcl-2 is accomplished by cellular mechanisms involving a
variety of different kinases, such as JNK (c-Jun N-terminal kinase)
and ERK1/2 (extracellular signal-regulated kinases).[35] The
regulatory function of Bcl-2 can also be modified through the
activation of pro-death molecules, such as epothilone B, which
induces Bax (Bcl-2 associated X-protein) translocation to the
mitochondria accompanied by cytochrome-c release into the
cytosol, triggering the mitochondrial apoptosis pathway through
the interaction of Bax with Bcl-2 and Bcl-xL.[36,37]
We investigated the phosphorylation status of Bcl-2 in human
L3.6pl pancreatic cancer cells and demonstrated that treatment
with either tubulysin A or pretubulysin lead to transiently
enhanced levels of phosphorylated Bcl-2 (pBcl-2) after 8 and
24 h treatments (Figure 5A). The highest pBcl-2 levels were
detected after either 24 h of tubulysin treatment or 8 h of
pretubulysin treatment. The initiation of Bcl-2 phosphorylation is
a common characteristic of antimitotic drugs. Although the
specific signaling events are only fairly understood, it is evident
that MAPK activation during the course of treatment with
tubulin-targeting agents is often linked to the phosphorylation
status of Bcl-2.[38] Bcl-2 abrogates the release of cytochrome-c
from mitochondria and subsequently the activation of caspase-9
and caspase-3.[39,40]
Here, we demonstrated that treatment with pretubulysin and
tubulysin A leads to the cleavage of poly(adenosine diphosphate-
ribose) polymerase (PARP), which is a substrate of caspase-3 and
functions in DNA damage detection and repair.[41,42] PARP
cleavage was detectable after a 24 h treatment with either drug,
and this effect was even more pronounced after 48 h (Figure 5B).
However, the apoptotic events initiated by tubulysin A and
pretubulysin in cancer cells are only partly caspase-dependent.
Treatment of L3.6pl cells with either compound resulted in
approximately 50% apoptotic cells relative to the control as
assessed by propidium iodide (PI) staining (Figure 6A). The broad-
spectrum caspase inhibitor Q-VD-OPh reduced drug-induced
apoptosis from approximately 46% to 26% and from 39% to 27%
for tubulysin A and pretubulysin, respectively (Figure 6B).
Comparative High-Content Screening (HCS)
In the course of HCS studies, we compared tubulysins with two
other antimitotic compounds of myxobacterial origin, disorazol A
and epothilone B, with a focus on microtubule-disrupting events.
Disorazol A was originally isolated from the Sorangium cellulosum
Figure 3. Tubulysin A and pretubulysin inhibit clonogenic survival of L3.6pl cells. L3.6pl cells were stimulated for 4 h and then seeded at
low confluence. After 6 d, the cells were stained with crystal violet, and the absorbance was measured at 550 nm (n= 3; *p#0.05 Anova/Dunnett).
doi:10.1371/journal.pone.0037416.g003
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strain So ce12 [43] and was shown to be a highly potent cytostatic
compound, with GI50 values against mammalian cells in the low
picomolar range, by inhibiting microtubule formation.[44]
Epothilone B was isolated from a Sorangium cellulosum strain (So
ce90) due to its very high antifungal potential.[14] Epothilone B
acts similar to taxanes by stabilizing microtubules.[45]
For the HCS of human U-2 OS osteosarcoma cells, the final
concentrations of the compounds were adjusted based on their
growth inhibitory potential, and cells were treated for 24 h. a-
Tubulin was probed by immunofluorescence, nuclei were stained
with Hoechst 33342, and HCS CellMaskTM Red stain was added
to facilitate subsequent segmentation of the cytoplasmic region.
The most obvious features were the enlargement of cells, the
fragmentation of nuclei, and the rearrangement of the microtubule
structure. Analyses were thus performed on a single-cell basis and
averaged over the complete sample. In a supervised, but unbiased
approach we found that standard deviation of tubulin fluorescence
and shape parameters of the cytoplasmic segments are the most
suitable to describe antimitotic phenomena. This was done by
experimentally creating a test set and classification in six cellular
states. All fluorescence parameters that can in principle be
investigated using the automated microscope were extracted,
and important features were defined and cross-validated by using
statistical methods (J. Herrmann, R. Mu¨ller et al., unpublished
results). Certain characteristic parameters for every cellular change
were then calculated within either the nuclear or cytoplasmic
Figure 4. Typical cellular events upon pretubulysin treatment. A) Isolated DNA of human promyelocytic HL-60 cells treated with
pretubulysin (1: control, 2: 30 nM, 24 h; 3: 75 nM, 24 h; 4: 30 nM, 48 h; 5: 75 nM, 48 h; 6: standard 1000 bp ladder; 7: standard 100 bp ladder). B)
Human U-2 OS osteosarcoma cells that were left untreated (upper panel) or were treated for 24 h with pretubulysin (lower panel). Microtubules are
visualized by immunofluorescence staining of a-tubulin (pseudocolor green), and nuclei were stained with Hoechst 33342 (pseudocolor blue). The
arrows indicate the abnormal accumulation of microtubules in cells after treatment with 25 nM pretubulysin; fragmented nuclei, and completely
depolymerized microtubules were observed at a drug concentration of 50 nM.
doi:10.1371/journal.pone.0037416.g004
Figure 5. Immunoblot analysis of tubulysin A- or pretubulysin-treated L3.6pl pancreatic cancer cells. The cells were treated for the
indicated time points with 10 nM tubulysin A or 10 nM pretubulysin. Lysates were immunoblotted for A) Bcl-2 and phosphorylated Bcl-2 (pBcl-2) or
B) for PARP; b-actin served as a reference for the quantification of the protein levels. Ctrl.: lysates of untreated control cells.
doi:10.1371/journal.pone.0037416.g005
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segments. Additionally, the standard error of the mean (SEM) was
calculated for average values derived from single cells within a
well. Throughout all HCS experiments the SEM values increased
with increasing concentrations of the compounds, which is due to
larger numbers of apoptotic cells and therefore more heteroge-
neous cell populations mainly with regards to cell size.In
accordance with the growth inhibition induced by all of the tested
compounds, the cell bodies were significantly enlarged in a
concentration-dependent manner (Figure 7). This cytopathic effect
is common to many cytostatic compounds and is particularly
characteristic of antimitotics. Thus, epothilone B, a microtubule
stabilizer, yields the same macroscopic characteristics as the other
microtubule-depolymerizing compounds in the test panel. Upon
treatment with the reference compounds tubulysin D, disorazol A,
and epothilone B, a slight drop can be observed at the highest
concentration tested, which is due to rounded-up, late apoptotic
cells. In addition, the standard deviation (SD) of microtubule
fluorescence, which serves as a measure of the tubulin distribution
within cells, peaks at the intermediate concentrations used in the
HC assays for all microtubule-destabilizing compounds (Figure 8).
In our hands, the SD of tubulin fluorescence has shown to be a
robust measure to describe microtubule disruption in various
assays. The more uniform tubulin appears in the cells, the lower
the SD is, i.e., the lowest SD values are observed for cells with
completely depolymerized microtubules. We observed a maxi-
mum value at intermediate concentrations, followed by a decline
at higher concentrations; for tubulysin D, a second peak was
observed at the highest concentrations due to cell debris. Upon
image data dereplication (Figure 9), it was apparent that an
increase in the tubulin fluorescence SD and the peak SD are linked
to the initial depolymerizing effect, which is characterized by a
greater number of mitotic cells with abnormal spindle pole
structures and a higher density of interphase microtubules around
the periphery of the cells. Increasing concentrations then led to the
complete depolymerization of microtubules, as indicated by the
lower SDs of the tubulin fluorescence. These characteristics were
evident for all tubulin-destabilizers and, most interestingly, for the
small pretubulysin precursor V. In summary, we assume that the
dynamics of pretubulysin-induced microtubule depolymerization
are highly comparable to those observed with the reference
compounds tubulysin A/D and disorazol A. For epothilone B, we
basically observed a continuous increase in the tubulin fluores-
cence SD due to the stabilizing effects of this compound. At the
highest epothilone B concentration the fluorescence SD slightly
falls off, which is most likely due to the very pronounced
microtubule-stabilizing effect.
The analysis of nuclear fragmentation revealed a concentration-
dependent increase in the nuclear fluorescence intensity accom-
panied by a higher variability in the intensities within single nuclei
(data not shown). In a more detailed study on DNA double-strand
breaks (DSBs), we found that all tested drugs led to large cH2A.X
foci that were exclusively associated with already fragmented
nuclei. Phospho-histone cH2A.X is widely used as a marker for
DSBs because H2A.X is phosphorylated on serine residue 139
within seconds after the induction of DSBs in mammalian
cells.[46,47] Here, we treated the cells as in the microtubule
HCS but for 48 h instead of 24 h. The cells were segmented on
nuclear ROIs (regions of interest), and the immunofluorescence of
cH2A.X was measured (Figure S2). Our results suggest that the
tested drugs do not directly induce DSBs at sublethal concentra-
tions but initiate downstream signaling, finally leading to enhanced
H2A.X phosphorylation, which can only be found in at least
partially fragmented nuclei (Figure 10).
Inhibition of cancer cell migration
Tumor cell migration is directly linked to metastasis and is one
of the most promising targets in cancer therapy; the inhibition of
tumor cell migration may decrease the metastatic capacity of solid
tumors. [48,49]
In our studies on tumor cell motility, we used the metastatic
human L3.6pl pancreatic cancer cell line. The stimulation of
L3.6pl cells with a 3 nM concentration of either compound led to
a significant reduction in migration in scratch assays (Figure 11A)
to approximately 50% of the cell-covered area relative to the
untreated control population (FCS supplemented; 100%). In
addition, treatment with 1 nM tubulysin A or pretubulysin
reduced the relative number of migrated L3.6pl cells to
approximately 40% of the control value (FCS supplemented;
100%) in a Boyden chamber assay. The number of migrating cells
could be even further reduced to 30% of the control at drug
concentrations of 10 nM (Figure 11B). It is hereby noticeable, that
inhibition of migration is not due to apoptotic events after
treatment with pretubulysin or tubulysin, as apoptosis induction in
L3.6pl cells was seen as late as 48 h after treatment with 1 nM of
either tubulysin A or pretubulysin. This treatment led to only 20%
apoptosis induction in L3.6pl cells (Figure 6).
In vitro studies on tubulin
Naturally occurring tubulysins A-I differ by up a factor of 60 in
their inhibitory potency against L-929 mouse fibroblasts. Potency
is thought to be primarily influenced by the lipophilicity of the
compound. Tubulysin D is the most lipophilic, and thus, is also the
most active of the derivatives. These findings are highlighted by
the results of in vitro tubulin polymerization studies that showed
only minor differences in the overall activities of the tested
tubulysins.[50] We were also interested in comparing the in vitro
activities in a cell-free system of tubulysin A, pretubulysin, and
pretubulysin’s small precursor V to elucidate whether the synthetic
pretubulysins exhibit similar tubulin-binding potencies without the
cell membrane acting as a natural barrier.
Figure 6. Induction of apoptosis in L3.6pl cells. The cells were
treated for 48 h with A) varying concentrations of tubulysin A or
pretubulysin (n = 2) or B) with 10 nM drug in conjunction with 10 mM
caspase inhibitor Q-VD-OPh (n = 3). The percentages of apoptotic cells
in the whole cell population were determined by PI staining (*p#0.05
Anova/Dunnett).
doi:10.1371/journal.pone.0037416.g006
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As a reference, we recorded the absorbance of microtubule
protein at 350 nm over time for 10 mM tubulin and demonstrated
that the addition of 1 mM tubulysin A led to an approximately
50% reduction in built-up microtubules (Figure 12A). The
corresponding electron micrographs reveal perfect tubular struc-
tures and long microtubules in the control. Upon the addition of
tubulysin A, a smaller number of shorter and disrupted
microtubules were observed. Similar to previous studies on
tubulysin A [31], we demonstrated that pretubulysin can inhibit
microtubule formation in vitro in a dose-dependent manner and
can also depolymerize already assembled microtubules
(Figure 12B). The addition of 1 mM pretubulysin (pre-assembly)
led to an approximately 50% reduction in microtubule formation,
whereas approximately 2 mM pretubulysin was needed to reduce
the number of already built-up microtubules to the same extent.
Electron micrographs of 12 mM tubulin incubated with 5 mM
pretubulysin revealed that higher concentrations of the drug are
needed to fully destroy microtubules rather than inhibit assembly.
The pre-assembly addition of pretubulysin fully inhibited the
polymerization process because only single protein blocks were
found. In contrast, the post-assembly addition did not lead to
complete depolymerization; thus, shorter and disrupted microtu-
bule structures were observed.
Furthermore, we studied the effect of pretubulysin precursor V
(Figure 1) and observed an approximately 10-fold reduction in
activity as measured by the in vitro inhibition of tubulin
polymerization (Figure 12C). Electron micrographs revealed that
treatment with either 2 mM pretubulysin or 25 mM pretubulysin
precursor V yields similar results with respect to microtubule
Figure 7. HC Analysis of the cytoplasmic area of U-2 OS cells treated with antimitotic compounds. A) Representative segmentation
images of control U-2 OS cells and epothilone B- or pretubulysin-treated cells that were acquired with 200-fold magnification on a BD Pathway 855
automated microscope and subsequently processed and analyzed in AttoVision v1.6.2. B) Representative results of HC analyses of the average
cytoplasmic area of U-2 OS osteosarcoma cells treated for 24 h with antimitotic drugs at varying concentrations. Bars represent the mean 6 SEM of
all cellular segments within a well.
doi:10.1371/journal.pone.0037416.g007
Figure 8. HC analysis of the standard deviation of tubulin fluorescence. Representative HCS results of several experiments on tubulin
depolymerization. The SD is used as a proxy for the tubulin distribution within the cytoplasmic segment of U-2 OS osteosarcoma cells treated for 24 h
with antimitotic drugs at varying concentrations. Arrows indicate peak SD values for depolymerizing agents due to the higher density of
microtubules at intermediate drug concentrations. Bars represent the mean 6 SEM of all cellular segments within a well.
doi:10.1371/journal.pone.0037416.g008
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disruption, as depicted by the shortened microtubules and the
perturbed tubular structure relative to the control.
Taken together, our results suggest that pretubulysin is
comparably potent to the parent tubulysin A with respect to
microtubule disruption in vitro. Thus, we assume that pretubulysin
has a similar binding affinity. The small precursor V was
significantly less active, suggesting not only that cellular uptake
or reduced metabolic stability causes the loss of growth inhibition
activity but also that the binding affinity to purified tubulin is
reduced.
Conclusion
We demonstrated that synthetically accessible pretubulysin
exhibits only a minor reduction in potential anticancer activity
relative to the parent compound tubulysin, as seen in cell-based
and in vitro studies. With a synthetic route in hand, pretubulysin
or its derivatives appear to be better-suited for the development of
novel antimitotic agents in tumor therapy, including tumor-
targeting constructs, because the supply issues commonly encoun-
tered in the preclinical development of pharmaceuticals from
natural products have been circumvented. Studies on further
simplified pretubulysins are currently ongoing.[51] Although the
activity of a direct synthetic precursor of pretubulysin was reduced,
we demonstrated that even a very small molecule (precursor V),
consisting only of two out of the four original amino acids, can
bind to tubulin in vitro and cause microtubule depolymerization in
cell-based assays. Thus, we believe that pretubulysin can be easily
modified by means of further simplification and the attachment of
various functional groups. Future synthetic approaches will
thereby aid in obtaining greater insight into the mode of action
of this compound family and will allow the ‘fine-tuning’ of the
target binding, toxicity, and tumor specificity properties of
pretubulysin.
Materials and Methods
Compounds and chemicals
The reference compounds epothilone B, disorazol A, and
tubulysins A and D were kindly provided by the Microbial Drugs
research group (MWIS) at the Helmholtz Centre for Infection
Research (HZI, Braunschweig, Germany). All chemicals were of
reagent grade quality and were obtained from commercial sources
and used without further purification.
Cell cultures
The L3.6pl cell line [52] was kindly provided by C. J. Bruns
(Department of Surgery, Clinic Großhadern, LMU Munich,
Germany). All other cell lines were obtained from the American
Type Culture Collection (ATCC) and the German Collection of
Microorganisms and Cell Cultures (Deutsche Sammlung fu¨r
Mikroorganismen und Zellkulturen, DSMZ). All cell lines were
cultured under the conditions recommended by the respective
depositor. L3.6pl cells were cultured in RPMI medium supple-
mented with 10% FCS, 1 mM pyruvate, 1% non-essential amino
acids) and cultureware was coated with collagen G (0.001%
Figure 9. HC images of control U-2 OS cells and cells treated with pretubulysin. a-Tubulin was visualized by immunofluorescence, and
images were acquired with 200-fold magnification on a BD Pathway 855 automated microscope. The background shows the details of the HC analysis
of the SD of tubulin fluorescence (Figure 8).
doi:10.1371/journal.pone.0037416.g009
Figure 10. Representative images of U-2 OS cells treated with
100 nM epothilone B or pretubulysin for 48 h. Nuclei were
stained with Hoechst 33342 (pseudocolor blue, left panel), and cH2A.X
was visualized by immunofluorescence (pseudocolor red, right panel).
Arrows indicate fragmented nuclei with bright fluorescent spots due to
H2A.X phosphorylation events. Images were acquired on a BD Pathway
855 automated microscope and subsequently processed and analyzed
in AttoVision v1.6.2 (the full HCS analysis is provided as supplementary
material, Figure S2).
doi:10.1371/journal.pone.0037416.g010
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collagen/PBS). Media were purchased from Sigma or PAA, fetal
bovine serum (FBS) and non-essential amino acids were from
PAA, pyruvate was purchased from Sigma, and other reagents
were from GIBCO (Invitrogen). Plasticware was obtained from
Nunc, Sarstedt, BD Biosciences, and Corning.
Cell cycle analysis
Cells were seeded in 6-well plates in 5 mL of complete medium
and, after an o/n equilibration, were treated with the compounds
dissolved in methanol at the appropriate concentrations and for
the time periods indicated in the text. Approximately 106 cells
were harvested by centrifugation, washed twice with PBS
(phosphate-buffered saline, pH 7.4) and fixed in cold (220uC)
80% methanol. After an o/n fixation at 220uC, the cells were
washed with PBS and further permeabilized with 0.1% saponin in
PBS. For DNA staining, the cells were resuspended in staining
solution containing 20 mg mL21 propidium iodide (PI) and
100 mg mL21 ribonuclease A (RNase A) in PBS. The cells were
stained for 30 min at 37uC and analyzed on a GUAVA EasyCyte
Plus flow cytometer (Millipore). In total, 104 events, excluding cell
debris, were measured, and the data were processed using FlowJo
v7.6.5 software (Tree Star Inc.). For cell cycle analysis, the Dean-
Jett-Fox algorithm was used.
Clonogenic survival
L3.6pI cells at 70% confluence were treated for 4 h. After the
treatment, the cells were trypsinized, and 104 L3.6pl cells were
seeded in a 6-well plate. The freshly seeded cells were allowed to
grow for 6 d, followed by crystal violet staining for 10 min.
Pictures of the wells were taken, and the crystal violet was
redissolved with sodium citrate solution to measure absorption at
550 nm in a SpectraFluor PlusTM (Tecan, Ma¨nnedorf, Austria).
For statistical analysis, the percentage of viable cells for untreated
cells was set to 100%.
DNA ladder detection
DNA fragments were extracted from apoptotic cells in
phosphate-citrate buffer (PCB, pH 7.8) as described by Gong et
al.[53] In brief, cells were harvested by centrifugation and fixed o/
n at 220uC in 70% ethanol. The extraction was performed by
resuspension in PCB buffer, which consisted of 24 parts 0.2 M
Na2HPO4 and 1 part 0.1 M citric acid. The supernatant was then
treated with 0.25% Nonidet NP-40, RNase A, and proteinase K.
The extracted DNA was loaded onto an agarose gel (1.7%) and
separated by 4 h of electrophoresis at 4 V/cm using 0.56 TBE
buffer (45 mM Tris-borate, 1 mM EDTA). The resulting bands
were stained with ethidium bromide and detected under UV light.
Figure 11. Inhibition of L3.6pl pancreatic cancer cell migration by pretubulysin and tubulysin A. A) ‘Wound healing’ assay. A confluent
layer of L3.6pl was scratched and either left untreated or stimulated with varying concentrations of drug (n = 2). Left panel: Regions covered with cells
are shown in yellow, and uncovered areas are displayed in gray. Right panel: The percentage of migration is expressed relative to the starvation
control (0%) or the untreated control containing FCS (fetal calf serum; 100%). B) Boyden chamber assay with L3.6pl cells that were left untreated or
stimulated with 1 or 10 nM drug (n = 2). Cells migrating toward a FCS gradient were stained with crystal violet (left panel), and the percentage of
migration (right panel) was expressed relative to the levels of migration for the negative controls with (100%) or without FCS (*p#0.05 Anova/
Dunnett).
doi:10.1371/journal.pone.0037416.g011
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Immunoblotting
Proteins were separated by SDS-PAGE and transferred to
nitrocellulose membranes via tank blotting. Nitrocellulose mem-
branes were incubated with antibodies raised against Bcl-2
(Calbiochem), PARP (Calbiochem) or actin (Millipore). To detect
the protein levels, the ECLTM detection system (Amersham
Pharmacia Biotech, Little Chalfont, UK) or the Odyssey Infrared
Imaging system version 2.1 (LI-COR Biosciences, Lincoln, NE,
USA) was used.
Apoptosis measurement
Apoptotic cell death was measured as described by Nicoletti et
al.[54] Briefly, cells were permeabilized with a Triton-containing
buffer and stained with 50 mg mL21 propidium iodide. The cells
were analyzed by flow cytometry.
HCS studies
Human U-2 OS osteosarcoma cells were seeded at 56103 cells
per well in 96-well imaging plates (BD Falcon). After an o/n
equilibration, the cells were treated with antimitotic drugs,
reference drugs, and a solvent control at the appropriate
concentrations and treatment periods indicated for each experi-
ment. The cells were fixed with cold (220uC) acetone/MeOH
(1:1) for 10 min. After washing with PBS, the cells were
permeabilized with 0.01% Triton-X 100 in PBS. The following
combinations of primary and secondary antibodies were used: a-
tubulin mAb (1:2000, Sigma)/goat-anti-mouse-Alexa 488 (1:1000,
Molecular Probes) and phospho-Histone cH2A.X (Ser139) mAb
Figure 12. In vitro inhibition of tubulin polymerization by tubulysin A, pretubulysin and a small precursor of pretubulysin. A) As a
reference, 1 mM tubulysin A was added to a preparation of 10 mM tubulin, and the absorbance was measured over time at 350 nm; the maximum
value of the untreated control was set to 100%. Electron micrographs of the corresponding samples are shown on the right. B) Pretubulysin was
either added pre-assembly (left panel) or post-assembly (right panel; the arrow indicates the time at which the drug was added) to a preparation of
10 mM tubulin, and the absorbance was measured at 350 nm; the maximum value of the untreated control was set to 100%. The electron
micrographs in the upper corners display different degrees of disruption for both treatment types caused by pretubulysin. C) Tubulin protein was
treated pre-assembly with either pretubulysin or its precursor, and the absorbance at 350 nm was measured and then expressed relative to the
absorbance of the tubulin control (100%). Electron micrographs show disrupted microtubules upon treatment with pretubulysin or its precursor V.
The scale bar on each micrograph is 500 nm.
doi:10.1371/journal.pone.0037416.g012
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(1:400, Millipore)/goat-anti-mouse-Alexa 488 (1:1000, Molecular
Probes), each diluted in PBS/10% FBS. For labeling, cells were
incubated with primary antibody for 45 min at 37uC, followed by
incubation with the secondary antibody under the same condi-
tions. The nuclei were stained with Hoechst 33342 (5 mg mL21;
Molecular Probes), and a whole cell stain (1 mg mL21; HCS
CellMaskTM Red stain, Invitrogen) was used to facilitate later cell
segmentation. The samples were imaged on an automated
microscope (BD Pathway 855) suitable for high-content screening
with appropriate filter sets for Alexa 488, Hoechst, and
CellMaskTM Red fluorescence. For the analysis of microtubules,
a dual mask for the cytoplasm and nuclei was used in the
CellMaskTM Red and Hoechst channels, respectively, and the
assigned parameters were calculated in either one of these ROIs as
indicated. For the DSB analyses, a polygon nuclear mask was
used, and cH2A.X fluorescence was calculated within this ROI.
The average values per well are given.
Scratch assay
L3.6pl cells were seeded 1 d before stimulation. The confluent
cell layer was scratched, and tubulysin/pretubulysin that had been
diluted in culture media was added. Scratched and treated cells
were incubated at 37uC for 16 h. Cells were fixed with 3% PFA,
and images were taken using a microscope (Axiovert, Zeiss). The
analysis was performed with WimScratch software (Wimasis,
Munich, Germany).
Migration assay (Boyden chamber)
For each Boyden Chamber, 105 L3.6pl cells were resuspended
in media without FCS and added on top of the Boyden chamber
membrane. Tubulysin/pretubulysin was also added to this
suspension. On the bottom of the Boyden chamber membrane,
culture media containing 10% FCS+100 ng mL21 EGF was
added. During cell migration, the chambers were incubated at
37uC in 5% CO2 for 16 h. Migrated cells were fixed and stained
with crystal violet/methanol. Non-migrated cells on the top of the
chamber were removed with a cotton swab. Images were acquired,
and the migrated cells were counted and normalized relative to
control cells, which represent 100% migration.
Tubulin isolation
Microtubule proteins were isolated from porcine brain tissue as
described elsewhere.[55] In brief, brains were homogenized in
PEM buffer (0.1 M PIPES, pH 6.6; 1 mM EGTA; 1 mM
MgSO4) in the presence of 0.1 mM GTP and 2.5 mM ATP,
followed by three cycles of temperature-dependent depolymeriza-
tion and polymerization. Purified tubulin was either stored at
280uC or directly used in turbidimetric assays.
Tubulin polymerization assays
Tubulin polymerization was analyzed in a turbidimetric
assay.[56] The samples (200 mL, 10 mM tubulin) in PEM
polymerization buffer containing 1 mM GTP were added to ice-
cooled cuvettes. These cuvettes were then placed in a water-
jacketed cuvette holder in a diode array photometer (Beckman
spectrophotometer DU7500) and rapidly warmed to 37uC. The
absorbance at 350 nm in the presence and absence of drugs is
proportional to the degree of tubulin polymerization.
Transmission electron microscopy
MAP-enriched tubulin from porcine brain tissue (70% tubulin,
30% microtubule-associated proteins; Cytoskeleton, Inc.) was
adjusted to 12 mM tubulin with PEM buffer containing 1 mM
GTP and polymerized for 30 min at 37uC in the presence or
absence of drugs. For negative staining, thin carbon support films
were prepared by indirect sublimation of carbon on freshly cleaved
mica. Samples were then absorbed to the carbon film and
negatively stained with 2% (wt/vol) aqueous uranyl acetate
(pH 4.5). After air drying, samples were examined in a Zeiss
TEM 910 at an acceleration voltage of 80 kV and at calibrated
magnifications using a line grid replica. Images were recorded
digitally with a Slow-Scan CCD-Camera (ProScan, 102461024,
Scheuring, Germany) with ITEM-Software (Olympus Soft Imag-
ing Solutions, Mu¨nster, Germany).
Supporting Information
Figure S1 Chemical structures of tested tubulysin
analogs and their GI50 values on L-929 cells. GI50 values
are given in bold and were determined in a tetrazolium salt (MTT)
assay. L-929 cells were treated for 5 d and values present the
average of two independent measurements. The numbering of
tested analogs refers to Figure 1.
(TIF)
Figure S2 HC analysis of cH2A.X fluorescence within
the nuclear segment of U-2 OS cells. The cells were treated
for 48 h with antimitotic drugs at varying concentrations. For
imaging, cells were fixed, cH2A.X was probed by immunofluo-
rescence, and nuclei were stained with Hoechst33342. Nuclear
segments were defined in Hoechst channel and intensity of
phosphorylated H2A.X was calculated within these segments.
Increasing intensities upon treatment with antimitotics is exclu-
sively related to fragmented nuclei. The image in the upper left
corner gives a detail of cells treated with the positive control
10 mMHU (hydroxyurea) and shows induced DSBs (DNA double-
strand breaks) as determined by cH2A.X. Images were acquired
on a BD Pathway 855 automated microscope and subsequently
processed and analyzed in AttoVision v1.6.2. Bars represent the
mean 6 SEM of all cellular segments within a well.
(TIF)
Table S1 Calculated percentage of HepG2 cells in G1, S,
and G2/M phase of the cell cycle as determined by flow
cytometry.
(DOC)
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